| Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. | |
| | |
MedLine Citation:
|
PMID: 19567452 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: We evaluated efficacy and safety of early and short-term prophylaxis with acenocumarine or dalteparin in the prevention of non-occlusive or occlusive central vein catheter-related thrombosis (CVCrT). PATIENTS AND METHODS: Consecutive cancer patients scheduled for chemotherapy randomly received: acenocumarine 1 mg/day for 3 days before and 8 days after central vein catheter (CVC) insertion; dalteparin 5000 IU 2 h before and daily for 8 days after CVC insertion; no anticoagulant treatment (NT). All patients underwent venography on days 8 and 30, some of them on days 90, 150 and 210 after CVC. RESULTS: A total of 450 patients were randomized, 348 underwent at least two venography. Both acenocumarine and dalteparin reduced venography-detected CVCrT rate [21.9% acenocumarine versus 52.6% NT, odds ratio (OR) 0.3, P < 0.01; 40% dalteparin versus 52.6% NT, OR 0.6, P = 0.05]. Acenocumarine was more effective than dalteparin (OR 0.4, P = 0.01). The rate of occlusive CVCrT was not different in the three groups (0.9% acenocumarine, 3.3% dalteparin, 1.8% NT; P = 0.40). Most CVCrTs (95.6%) were observed on day 8 after CVC insertion and were non-occlusive. CONCLUSIONS: In this study of early and short-term prophylaxis, acenocumarine was more effective than dalteparin on non-occlusive and asymptomatic CVCrT events. The first days following CVC insertion represent the highest risk for CVCrT. |
| | |
Authors:
|
M De Cicco; M Matovic; L Balestreri; A Steffan; R Pacenzia; M Malafronte; D Fantin; C A Bertuzzi; F Fabiani; S Morassut; E Bidoli; A Veronesi |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2009-06-30 |
Journal Detail:
|
Title: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO Volume: 20 ISSN: 1569-8041 ISO Abbreviation: Ann. Oncol. Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2010-01-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9007735 Medline TA: Ann Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 1936-42 Citation Subset: IM |
Affiliation:
|
Department of Anaesthesiology and Intensive Care, National Cancer Institute, Aviano (PN), Italy. mdecicco@cro.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acenocoumarol
/
administration & dosage,
therapeutic use* Aged Anticoagulants / administration & dosage, therapeutic use* Catheterization, Central Venous / adverse effects* Dalteparin / administration & dosage, therapeutic use* Female Humans Male Middle Aged Neoplasms / complications, therapy* Phlebography* Thrombosis / complications, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Dalteparin; 152-72-7/Acenocoumarol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients...
Next Document: Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous s...